

Ocimum Biosolutions launches the Software as a Service version of its Biotracker™ Biobanking LIMS

Posted: 24 Jun 2010 12:04 AM PDT

Hyderabad, Andhra Pradesh, India, June 24, 2010: Ocimum Biosolutions, a leading provider of Life Sciences Laboratory Information Management Systems (LIMS) and genomic solutions, is pleased to announce that it has launched Biotracker™ for Biobanking SaaS, the Software as a Service version of its LIMS for biorepositories.

Biotracker™ Biobanking is a fully scalable, configurable, customizable, complete biobanking solution. Now that Biotracker™ Biobanking is available as a Software as a Service (SaaS), biobanks will be able to utilize the system over the internet without the need for increasing their IT infrastructure or workload.

“Having run and managed biobanks for both our own labs and for a variety of customers for many years, Ocimum Biosolutions has demonstrable working expertise in this domain”, stated Anu Acharya, CEO of Ocimum Biosolutions. “We leveraged our biobanking domain expertise when designing our Biotracker™ Biobanking solution and now we have leveraged our IT expertise to make Biotracker™ Biobanking available as a hosted service over the internet. This is a part of our ongoing efforts to bring RaaS (Research as a Service) to our partners”, continued Ms. Acharya.

Biotracker™ Biobanking has specialized features that include a Requester Module, Donor/Patient and Biospecimen Management with full Genealogy, Unlimited Meta Data Annotation, Controlled Vocabulary and Synonyms, Data and Location Management, TMA, CMA, and much more. Biotracker™ Biobanking is caBIG® Bronze Certified, providing the highest degree of integratability and interoperability while also supporting Regulatory Compliancy (HIPAA, 21CFR11, GxP, CLIA, etc.)

About Biotracker™ Biobanking SaaS

Biotracker™ Biobanking SaaS offers an easy, "pay-as-you-go" solution for all current and long-term biobanking needs. Biotracker™ Biobanking SaaS now offers the benefit of a full featured Biobanking LIMS over the Internet to small and medium biobanking labs which previously would only be available within large enterprises. The intuitive user interface, ease-of-use and online access makes the adoption for use rate for Biotracker™ Biobanking SaaS very high by the lab personnel while simultaneously creating a better user experience. This greatly increases the likelihood of full utilization of all the system features yielding maximum value for a minimal investment.

For more details, please visit <http://www.ocimumbio.com/lims2/products/biotracker-biobanking-saas/>

About Ocimum Biosolutions

Ocimum Biosolutions is an integrated global genomic services company with operations in Hyderabad, India and Gaithersburg, MD. We provide comprehensive (research level and GLP-compliant) genomic services, reference databases, and LIMS solutions. Our distinct platform "Research as a Service" (RaaS) allows complete outsourcing of genomics – from storing biological samples and performing on demand DNA and RNA based services to validating biomarkers using our proprietary databases and providing data and bioinformatic analysis. We have been chosen as a global preferred outsourcing provider for more than 75% of top 25 pharma and biotech companies plus leading research institutes. Our partners recognize our expertise for understanding disease mechanisms in correlation with discovery, prioritization of gene targets and biomarkers, and sample analysis for clinical studies.

With our global infrastructure's standardized procedures, capacity, and highly skilled staff, we are capable of supporting drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification. Our expertise is unparalleled and was gained through the creation of the world's largest commercial gene expression databases – BioExpress® and ToxExpress®. Ocimum has been consistently ranked as India's fastest growing biotechnology company and one of the fastest growing technology companies over the last five years by Deloitte Touche Tohmatsu.

For more information, please visit www.ocimumbio.com